<DOC>
	<DOCNO>NCT00803530</DOCNO>
	<brief_summary>This prospective , multicenter phase II trial design evaluate safety activity combination association arsenic trioxide ( ATO ) ascorbic acid patient myelodysplastic syndrome</brief_summary>
	<brief_title>Study Association Arsenic Trioxide ( ATO ) Ascorbic Acid Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>1 . Patients affect myelodysplastic syndrome , enter one follow group : 1 . Myelodysplastic syndrome independent WHO diagnostic classification ( 43 ) IPSS prognostic score ( 2 ) , present least one follow abnormality : 3q26 chromosome rearrangement . High EVI1 transcript level . 2 . Myelodysplastic syndrome without excess blast ( nonRAEB patient ) low intermediate1 score risk accord IPSS ( 2 ) , second line treatment option , failure first line treatment erythropoietin +/ GCSF , immunosuppressive therapy , initial treatment modality . 3 . Non RAEB patient intermediate2 high risk score RAEB patient prognostic score , non candidate treatment conventional chemotherapy regimen . 2 . Presence one ore cytopenia characterise one ore follow element : Transfusions dependence . Hb &lt; 11 gr/dl Platelet count &lt; 50x109/L Absolute neutrophil count &lt; .5x109/L . 3 . ECOG Performance status â‰¤ 2 . 4 . Aged 18 80 . 5 . Life expectancy &gt; 4 month . 6 . Creatinine level &lt; 1.5 mg/dl . 7 . Liver function test , include ASLALTalkaline phosphatase low 3xULN 8 . No previous treatment chemotherapy , growth factor , cytokine experimental treatment within 4 week start treatment . 9 . No history clinically significant cardiac disease , include congestive heart failure . 10 . Cytogenetic evaluation available . 11 . Sending peripheral blood bone marrow sample central laboratory EVI1 rearrangement evaluation . 12 . Written Informed consent . 1 . Patients affect myelodysplastic syndrome enter category foreseen inclusion criterion point 1 . 2 . Absence cytopenia define contemporarily presence follow condition : ) transfusion need ; b ) Hb &gt; 11 gr/dl ; c ) platelet count &gt; 50x109/L ; ) absolute neutrophil count &gt; .5x109/L . 3 . All patient might candidate allogenic stem cell transplantation . 4 . Patients might candidate first line immunosuppressive therapy . 5 . ECOG Performance status &gt; 2 . 6 . Age low 18 high 80 . 7 . Life expectancy &lt; 4 month . 8 . Creatinine level &gt; 1.5 mg/dl . 9 . Liver function test , include ASLALTalkaline phosphatase high 3xULN 10 . Treatment chemotherapy , growth factor , cytokine experimental treatment within 4 week start treatment . 11 . Clinically significant cardiac disease , include congestive heart failure , rhythm abnormality , QT time &gt; 460m/s , need antiarrhythmic drug . 12 . Concurrent comorbid medical condition might exclude administration therapy , judge individual investigator . 13 . Absence cytogenetic evaluation . 14 . Participation time another study investigational drug use . 15 . Absence write Informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>arsenic trioxide</keyword>
	<keyword>ascorbic acid</keyword>
</DOC>